CMM Infraprojects Limited was originally set up as a Partnership Firm in 1979 in the name and style of M/s C.M. Mundra & Co. Subsequently the Partnership Firm was converted into Public Limited Company ...

Nintendo Switch 2 is finally confirmed. After literal years of unverified rumors, dubious leaks and copious amounts of online speculation, Nintendo has lifted the lid on its next-generation ...

But a consistently pale or light poop color may be a sign of a serious medical condition like hepatitis, gallstones, and other liver or biliary (bile duct or gall bladder) diseases. This article ...

Also, Nintendo Switch 2 launches into a changed market where players have come to expect that they will be able to carry their game libraries forward from one machine to another, which precluded a ...

If you are looking for the best rowing machine to bring rowing workouts into your home gym activity, there are quite a few you could choose from. They aren't a cheap piece of cardio equipment, but ...

The most common reason for cisplatin-ineligibility is renal function impairment. Up to 40% of patients with bladder cancer have renal impairment, defined as a creatinine clearance ≤60 ml/min, as ...

"One way to think about how Anktiva works is it is the first molecule, based on the package insert, that increases and proliferates the NK cells, the T cells, and the CD4+ and CD8+ T cells, without up ...

After rejecting ImmunityBio’s Anktiva last year, the FDA has cleared the drug as a treatment for bladder cancer, making it the company’s first commercial-stage product. Anktiva (nogapendekin ...

TASC is our industry’s premier peer-to-peer automation stage where America’s shop leaders refine the art of metalworking and CNC machining. For conference speakers, it's also an opportunity to ...

Get on the fast track to make an impact in one of today’s fastest growing fields with a machine learning master’s degree. The machine learning master’s program establishes the theoretical and ...

SunRISe-1 (NCT04640623) is an ongoing randomized, phase 2b study assessing efficacy and safety of TAR-200 + cetrelimab (Cohort 1), TAR-200 alone (Cohort 2), or cetrelimab alone (Cohort 3) in patients ...